Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD123 CAR-NK in Relapsed/Refractory AML or BPDCN
NCT06006403Phase 2Completed
- Sponsor
- Chongqing Precision Biotech
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD123 targeted CAR-NK cells in acute myeloid leukemia (AML), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Chongqing Precision Biotech. Started Mar 2024; status: completed.
02
Drugs
CD123 targeted CAR-NK cells
03
Conditions
acute myeloid leukemia (AML)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT06006403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006403.